{"id":953533,"date":"2026-04-22T06:03:14","date_gmt":"2026-04-22T10:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance\/"},"modified":"2026-04-22T06:03:14","modified_gmt":"2026-04-22T10:03:14","slug":"amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance\/","title":{"rendered":"Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance"},"content":{"rendered":"
\n

\n \u2013 Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity \u2013<\/em>\n <\/p>\n

\n \u2013 Transaction Accelerates Growth Profile and Diversification \u2013<\/em>\n <\/p>\n

\n \u2013 Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance \u2013<\/em>\n <\/p>\n

\n \u2013 Company to Host Investor Conference Call Today at 8:30 a.m. EST \u2013<\/em>\n <\/p>\n

BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. <\/strong>(Nasdaq: AMRX) (\u201cAmneal\u201d or the \u201cCompany\u201d), a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines, today announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC (\u201cKashiv\u201d) in a transaction with consideration that includes $375 million of cash and $375 million of equity payable at closing, plus up to $350 million in potential payments based on the achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing.<\/p>\n

Kashiv is among a select group of U.S.-based companies with proven end-to-end biosimilars capabilities across development and manufacturing, and a robust pipeline. This transaction will establish a scaled, fully integrated global biosimilars platform at a pivotal moment, ahead of a more than $300 billion projected global biologics loss-of-exclusivity wave over the next decade, accelerating growth and meaningfully extending and diversifying Amneal\u2019s long-term growth profile.<\/p>\n

\u201cAs biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market,\u201d said Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal. \u201cWith Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.\u201d<\/p>\n

\u201cThis acquisition establishes Amneal as a fully integrated global biosimilar platform at scale,\u201d said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal. \u201cBy combining Kashiv\u2019s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.\u201d<\/p>\n

\u201cWe are thrilled to combine Kashiv\u2019s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.,\u201d said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv. \u201cOur companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our collaboration of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies.\u201d<\/p>\n

The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions, and is expected to close in the second half of 2026.<\/p>\n

\n Compelling Strategic and Financial Benefits:<\/strong>\n <\/p>\n